The Department for Science, Innovation and Technology has published detailed eligibility criteria for the UK’s Life Sciences Large Investment Portfolio, setting a minimum £250 million investment threshold for companies seeking support across manufacturing and research and development projects.
The scheme, known as LSLIP, was announced in April 2026 as part of the government’s Life Sciences Sector Plan. Companies applying through the portfolio route must commit at least £250 million over three years to eligible UK life sciences manufacturing or R&D, with at least one project expected to begin within the following 12 months.
The eligibility criteria narrow the programme towards established operators rather than early-stage ventures or isolated plant upgrades. Applicants must be UK-registered companies or UK-registered establishments with at least one UK company in their group structure, be wholly private sector, and operate in medicines, medical technology, or diagnostics. They must also hold the regulatory approvals required for the activities covered by the proposed investment.
Financial requirements are similarly substantial. Applicants need three years of audited financial statements, must provide acceptable protection for public funds where grants are awarded, and need financial and corporate information that can be independently validated. The government also requires a record of successfully developing or manufacturing medicines or medical devices in the UK or internationally.
LSLIP is consequently structured around investment portfolios rather than single projects. A company could combine manufacturing and R&D expenditure across several UK locations, provided the overall commitment exceeds the threshold and at least one qualifying project enters delivery within a year. That gives government a mechanism for negotiating with groups whose investment decisions are often made between competing international sites rather than within a single domestic funding round.
Smaller projects continue to sit under separate programmes. The guidance directs standalone manufacturing investments above £8 million, or projects below the £250 million LSLIP threshold, towards the Life Sciences Innovative Manufacturing Fund. Large research programmes above £100 million may also qualify for the Transformational R&D Investment Fund pilot.
The funding architecture therefore separates projects by scale and purpose instead of placing all life sciences capital expenditure into one scheme. The Life Sciences Sector Plan commits up to £520 million in grants through the manufacturing fund, while the government’s subsidy register lists the large-investment portfolio with a £570 million budget and a maximum individual grant award of £130 million.
The criteria arrive during a wider attempt to attract manufacturing as well as laboratory research. Government announcements during 2026 have included investment in medicines, vaccines, specialist pharmaceutical processes, and associated production capacity, with policy increasingly focused on retaining more of the route from discovery through scale-up and commercial manufacture in the UK.
Recent company programmes illustrate the capital intensity involved. GSK’s £400 million programme across Cambridge and Ware combines a major research centre with laboratory upgrades linked to manufacturing scale-up, while Eisai’s investment at Hatfield adds temperature-controlled packaging and supply capability for medicines. Neither has been presented as an LSLIP award, but both show how modern life sciences investment can extend across research, process development, production, packaging, and distribution infrastructure.
Large pharmaceutical and medical technology programmes rarely depend on one building or production line. A multi-year investment can include process development, validation equipment, digital systems, utilities, cleanrooms, manufacturing lines, warehousing, and specialist skills across several sites. The £250 million threshold concentrates the scheme on portfolios large enough to include several of those elements.
The requirement for one project to begin within 12 months also places a practical constraint on speculative submissions. Applicants need enough technical definition, regulatory preparedness, financing certainty, and corporate commitment to move at least part of the portfolio towards delivery quickly, even where the wider programme extends across the full three-year investment period.
That timetable is important in a market where governments increasingly compete for internationally mobile pharmaceutical and medtech investment. Manufacturing projects can be directed towards jurisdictions offering combinations of grants, tax treatment, skilled labour, regulatory support, infrastructure, energy, and proximity to research centres. UK support therefore has to influence decisions before companies have already committed production capacity elsewhere.
The eligibility rules now give major investors a clearer basis on which to assess the programme. They also make the scheme deliberately selective: a £250 million portfolio, audited financial history, regulatory readiness, and a near-term project start exclude much of the sector by design.
The next meaningful measure will be the projects that enter the programme rather than the size of the funding envelope itself. If LSLIP attracts manufacturing and R&D portfolios that would otherwise have been placed outside the UK, it will have altered investment decisions; if not, another large industrial support scheme will have succeeded mainly in producing an impressively high entry threshold.
